Change of procalcitonin predicts clinical outcome of febrile episodes in patients with hematological malignancies
- 30 May 2006
- journal article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 14 (12) , 1241-1245
- https://doi.org/10.1007/s00520-006-0081-2
Abstract
Procalcitonin (PCT) was widely investigated in febrile neutropenia as an indirect marker of infection. Many institutions also use PCT as a tool to monitor the course of a febrile episode because increases in PCT values during the febrile episode were associated with development of complications. However, to date, no study systematically evaluated the accuracy of decreasing PCT values in predicting favorable outcomes of a febrile episode. The aim of this study was to evaluate the changes in PCT values after resolution of fever with regard to their predictive value of stable defervescence. PCT was studied prospectively in 94 febrile episodes of 35 patients with hematological malignancies. Sixty-seven episodes were associated with an increased level of PCT at the beginning. In these episodes, stable resolution of fever was significantly correlated with a decrease in PCT values. The best cut-off level to predict freedom from recurrence of fever for at least 5 days was p<0.001. Our study supports the value of PCT as a reliable tool to predict clinical outcome in febrile neutropenia.Keywords
This publication has 21 references indexed in Scilit:
- Prospective evaluation of procalcitonin in adults with febrile neutropenia after haematopoietic stem cell transplantationBritish Journal of Haematology, 2004
- Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicentre studyClinical Microbiology & Infection, 2004
- Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive proteinEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index scoreSupportive Care in Cancer, 2004
- Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropeniaCancer, 2004
- 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with CancerClinical Infectious Diseases, 2002
- Assessment of Procalcitonin as a Diagnostic Marker of Underlying Infection in Patients with Febrile NeutropeniaClinical Infectious Diseases, 2001
- Infections in the Neutropenic Patient— New Views of an Old ProblemHematology-American Society Hematology Education Program, 2001
- Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor IIBritish Journal of Haematology, 2000
- Diagnostic Value of Procalcitonin Serum Levels in Neutropenic Patients with Fever: Comparison with Interleukin-8Scandinavian Journal of Infectious Diseases, 1999